Jazz Pharma CFO has 3,343 shares withheld for tax
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals EVP & Chief Financial Officer Philip L. Johnson reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations. After this disposition, he directly holds 56,431 ordinary shares. A footnote also notes he acquired 166 ordinary shares under a Section 423 employee stock purchase plan on May 29, 2026.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Ordinary Shares | 3,343 | $237.72 | $795K |
Footnotes (2)
- F1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2. The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
Key Figures
Key Terms
restricted stock units financial
Section 423 Employee Stock Purchase Plan financial
tax obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Philip L. Johnson?
Was the Jazz Pharmaceuticals CFO’s Form 4 transaction an open-market sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.